

Targeting migration, survival, and immune response pathways in cancer

Amnon Peled

Company name-AlonBio*

Website AlonBio.com*

CEO name Arnon Aharon*

CATEGORY: Biotech/Pharma • Evolving trends in cancer therapeutics • AlonBio-Targeting Migration, Survival, and Immune-Response Pathways in Cancer •

Prof. Amnon Peled, Hadassah Hebrew University Hospital, Goldyne Savad Institute of Gene Therapy and CSO of AlonBio Ltd. • •

AlonBio is a late pre-clinical stage biotech company focused on the development of targeted anti-cancer treatments. • Using our screening platform MigHit™ we identified our lead compound BKT300 which is a selective, first in class, small molecule inhibitor of Protein Regulator of Cytokinesis 1 (PRC1). PRC1 is a scaffold protein that regulates key pathways crucial for cancer cell proliferation, survival, and metastasis. BKT300 has shown robust anticancer activity in disease relevant pre-clinical models and is developed as treatment for advanced/metastatic NSCLC, Breast cancer (including TNBC and HCC). BKT300 is currently tested in IND enabling Toxicology studies and will be IND ready in Q4/2024. The BKT300 first in human study is planned to start in Q1/2025 and PoC clinical readout expected during 2025-2026. • ImmunHit™ is a platform technology that enables the identification of small molecules targeting the IFN- γ /PDL-1 pathway which is critical in immunotherapy for cancer. Using this platform we already identified several molecular pathways and small molecules that as the potential to augment the immune response against cancer.